Bissan Al-Lazikani

List of Publications by Citations

Source: https://exaly.com/author-pdf/8792663/bissan-al-lazikani-publications-by-citations.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42 papers	8,172 citations	22 h-index	62 g-index
62 ext. papers	9,715 ext. citations	20.5 avg, IF	6.03 L-index

#	Paper	IF	Citations
42	How many drug targets are there?. *Nature Reviews Drug Discovery*, **2006**, 5, 993-6	64.1	2624
41	ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic Acids Research*, **2012**, 40, D1100-7	20.1	2257
40	A comprehensive map of molecular drug targets. *Nature Reviews Drug Discovery*, **2017**, 16, 19-34	64.1	1032
39	Combinatorial drug therapy for cancer in the post-genomic era. *Nature Biotechnology*, **2012**, 30, 679-92	44.5	670
38	Therapeutic opportunities within the DNA damage response. *Nature Reviews Cancer*, **2015**, 15, 166-80	31.3	329
37	Genomic-scale prioritization of drug targets: the TDR Targets database. *Nature Reviews Drug Discovery*, **2008**, 7, 900-7	64.1	244
36	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. *Nature Genetics*, **2018**, 50, 682-692	36.3	112
35	Objective assessment of cancer genes for drug discovery. *Nature Reviews Drug Discovery*, **2013**, 12, 35-50	64.1	89
34	Drug discovery in advanced prostate cancer: translating biology into therapy. *Nature Reviews Drug Discovery*, **2016**, 15, 699-718	64.1	77
33	Minimum information about a bioactive entity (MIABE). *Nature Reviews Drug Discovery*, **2011**, 10, 661-9	64.1	69
32	canSAR: an updated cancer research and drug discovery knowledgebase. *Nucleic Acids Research*, **2016**, 44, D938-43	20.1	67
31	canSAR: updated cancer research and drug discovery knowledgebase. *Nucleic Acids Research*, **2014**, 42, D1040-7	20.1	57
30	canSAR: an integrated cancer public translational research and drug discovery resource. *Nucleic Acids Research*, **2012**, 40, D947-56	20.1	50
29	PDBe-KB: a community-driven resource for structural and functional annotations. *Nucleic Acids Research*, **2020**, 48, D344-D353	20.1	50
28	Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. *Current Opinion in Pharmacology*, **2013**, 13, 486-96	5.1	44
27	Polypharmacology in Precision Oncology: Current Applications and Future Prospects. *Current Pharmaceutical Design*, **2016**, 22, 6935-6945	3.3	42
26	Objective, Quantitative, Data-Driven Assessment of Chemical Probes. *Cell Chemical Biology*, **2018**, 25, 194-205.e5	8.2	42

25	Drugging cancer genomes. *Nature Reviews Drug Discovery*, **2013**, 12, 889-90	64.1	42
24	The kinase polypharmacology landscape of clinical PARP inhibitors. *Scientific Reports*, **2020**, 10, 2585	4.9	32
23	Distinctive Behaviors of Druggable Proteins in Cellular Networks. *PLoS Computational Biology*, **2015**, 11, e1004597	5	30
22	canSAR: update to the cancer translational research and drug discovery knowledgebase. *Nucleic Acids Research*, **2019**, 47, D917-D922	20.1	29
21	Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. *ELife*, **2017**, 6,	8.9	23
20	canSAR: update to the cancer translational research and drug discovery knowledgebase. *Nucleic Acids Research*, **2021**, 49, D1074-D1082	20.1	21
19	Personalized medicine: patient-predictive panel power. *Cancer Cell*, **2012**, 21, 455-8	24.3	14
18	Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. *Oncogene*, **2019**, 38, 5905-5920	9.2	13
17	A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. *European Journal of Cancer*, **2013**, 49, 2512-21	7.5	11
16	Blocking the survival of the nastiest by HSP90 inhibition. *Oncotarget*, **2016**, 7, 3658-61	3.3	10
15	Rational design of non-resistant targeted cancer therapies. *Scientific Reports*, **2017**, 7, 46632	4.9	9
14	Public resources for chemical probes: the journey so far and the road ahead. *Future Medicinal Chemistry*, **2021**, 13, 731-747	4.1	9
13	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in -Mutant Cancers. *Molecular Cancer Therapeutics*, **2019**, 18, 1396-1404	6.1	8
12	PDBe-KB: collaboratively defining the biological context of structural data. *Nucleic Acids Research*, **2021**,	20.1	7
11	Unpicking the combination lock for mutant BRAF and RAS melanomas. *Cancer Discovery*, **2013**, 3, 14-9	24.4	6
10	SiGNet: A signaling network data simulator to enable signaling network inference. *PLoS ONE*, **2017**, 12, e0177701	3.7	5
9	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. *Cancer Research*, **2021**, 81, 1087-1100	10.1	5
8	Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. *Scientific Reports*, **2020**, 10, 16000	4.9	4

7	The Molecular Basis of Predicting Druggability1315-1334		3
6	Tuning Local Hydration Enables a Deeper Understanding of Protein-Ligand Binding: The PP1-Src Kinase Case. *Journal of Physical Chemistry Letters*, **2021**, 12, 49-58	6.4	3
5	Coronavirus canSAR: a Data-Driven, AI-Enabled, Drug Discovery Resource for the Research Community		2
4	Genomics, bio specimens, and other biological data: Current status and future directions. *Medical Physics*, **2018**, 45, e829-e833	4.4	2
3	Leveraging Human Genetics to Guide Cancer Drug Development. *JCO Clinical Cancer Informatics*, **2018**, 2, 1-11	5.2	1
2	Evolution of kinase polypharmacology across HSP90 drug discovery. *Cell Chemical Biology*, **2021**, 28, 1438-1445e3	8.1	3
1	Shouldn't enantiomeric purity be included in the minimum information about a bioactive entity? Response from the MIABE group. *Nature Reviews Drug Discovery*, **2012**, 11, 730-730	64.1	